Martin Michaud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Martin Michaud has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Francis Gaches
Department of Internal Medicine, Joseph Ducuing hospital, Toulouse, France
7 shared publicationsFlorian Catros
Department of Internal Medicine, Hopital Joseph Ducuing, Toulouse, France; Competence Center for Lysosomal Storage Diseases, Hopital Joseph Ducuing, Toulouse, France
5 shared publicationsSophie Ancellin
Department of Internal Medicine, Hopital Joseph Ducuing, Toulouse, France; Competence Center for Lysosomal Storage Diseases, Hopital Joseph Ducuing, Toulouse, France
4 shared publications- Geoffrey Urbanski
Department of Orofacial Sciences, School of Dentistry, University of California, San Francisco, CA, USA
2 shared publications Lucie Bidouze
Internal Medicine Department, Joseph Ducuing Hospital, Toulouse, France
2 shared publicationsOlivier Lidove
Service de médecine interne, centre de référence maladies lysosomales, GH Diaconesses Croix Saint-Simon, Paris, France
2 shared publications
Latest Publications
- 24 May 2025
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 46 (11) , 654-661
Déficit en sphingomyélinase acide (maladie de Niemann-Pick) : quand y penser ?
- 24 May 2025
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 46 (11) , 654-661
Déficit en sphingomyélinase acide (maladie de Niemann-Pick) : quand y penser ?
- 1 December 2021
- Published by Elsevier in Revue du Rhumatisme
- Vol. 88, A115
Les inhibiteurs de JAK dans la maladie de Still réfractaire
- 1 December 2021
- Published by Elsevier in Revue du Rhumatisme
- Vol. 88, A115
Les inhibiteurs de JAK dans la maladie de Still réfractaire
- Open Access
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 2991
Splenomegaly Study (SMS): Which Etiologies for Unexplained Splenomegalies?
The most prevalent etiologies of splenomegaly (SM) are easily detected in routine clinical practice. However, after these first-line diagnoses have be
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 2991
Open AccessSplenomegaly Study (SMS): Which Etiologies for Unexplained Splenomegalies?
The most prevalent etiologies of splenomegaly (SM) are easily detected in routine clinical practice. However, after these first-line diagnoses have be
- 1 May 2021
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 361 (5) , e41-E41
Umbilical Vein Recanalization
- 1 May 2021
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 361 (5) , e41-E41
Umbilical Vein Recanalization
- 1 December 2020
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 360 (6) , 641-649
When and How to Diagnose Fabry Disease in Clinical Pratice
- 1 December 2020
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 360 (6) , 641-649
When and How to Diagnose Fabry Disease in Clinical Pratice
- Open Access
- 1 October 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (10) , e133
Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine
Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine We read with interest the last 2019 update of the European League Against Rheumatism recommendations for the management of systemic lupus erythematosus (SLE). 1 We agree with the comment by Gabriel Figueroa-Parra et al concerning the lack of mention of chloroquine as major treatment in SLE. 2 Concerning survival, the LUMINA study group also showed that use of hydroxychloroquine (HCQ) was associated with a greater survival rate in 608 patients with SLE. 3 Ruiz-Irastorza et al confirmed these results in 232 patients with SLE. 4 The 15-year survival rate was 0.95 for patients using HCQ versus 0.68 for patients without antimalarial therapy. Finally, use of HCQ was also independently associated with a greater survival in a population of patients with SLE with nephritis. 5 The LUpus in MInorities, NAture versus nurture (LUMINA) study group also showed that patients without HCQ had higher damage scores and were more likely to have renal disease or central nervous system disease and use of HCQ was associated with a reduced risk of developing new damage in multivariate analysis. 3 The Canadian Hydroxychloroquine Study Group realised a double-blinded, placebo-controlled study that included patients with SLE to compare HCQ with placebo. 6 The risk of SLE flares (including major flares) increased by 2.5 at the end of the 6-months follow-up period in the placebo group compared with the HCQ group. During the additional 3 years follow-up study, use of HCQ reduced major flares by 57%. 7 Meinao et al published another double-blind placebo-controlled trial with chloroquine diphosphate steroid requirements and SLE Disease Activity Index score were higher in the placebo group and the flare risk was 4.6 times greater in the placebo group. 8 Moreover, patients with lower blood HCQ concentrations have greater SLE disease activity and have a greater risk of disease flare. 9 10 During pregnancy, HCQ use is essential. It reduces risks of pre-eclampsia, cutaneous neonatal lupus erythematosus, fetal growth restriction and prematurity. 11-13 In conclusion, HCQ is still in 2019, the cornerstone of the treatment of SLE.
- 1 October 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (10) , e133
Open AccessTreatment of systemic lupus erythematosus: don't forget hydroxychloroquine
Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine We read with interest the last 2019 update of the European League Against Rheumatism recommendations for the management of systemic lupus erythematosus (SLE). 1 We agree with the comment by Gabriel Figueroa-Parra et al concerning the lack of mention of chloroquine as major treatment in SLE. 2 Concerning survival, the LUMINA study group also showed that use of hydroxychloroquine (HCQ) was associated with a greater survival rate in 608 patients with SLE. 3 Ruiz-Irastorza et al confirmed these results in 232 patients with SLE. 4 The 15-year survival rate was 0.95 for patients using HCQ versus 0.68 for patients without antimalarial therapy. Finally, use of HCQ was also independently associated with a greater survival in a population of patients with SLE with nephritis. 5 The LUpus in MInorities, NAture versus nurture (LUMINA) study group also showed that patients without HCQ had higher damage scores and were more likely to have renal disease or central nervous system disease and use of HCQ was associated with a reduced risk of developing new damage in multivariate analysis. 3 The Canadian Hydroxychloroquine Study Group realised a double-blinded, placebo-controlled study that included patients with SLE to compare HCQ with placebo. 6 The risk of SLE flares (including major flares) increased by 2.5 at the end of the 6-months follow-up period in the placebo group compared with the HCQ group. During the additional 3 years follow-up study, use of HCQ reduced major flares by 57%. 7 Meinao et al published another double-blind placebo-controlled trial with chloroquine diphosphate steroid requirements and SLE Disease Activity Index score were higher in the placebo group and the flare risk was 4.6 times greater in the placebo group. 8 Moreover, patients with lower blood HCQ concentrations have greater SLE disease activity and have a greater risk of disease flare. 9 10 During pregnancy, HCQ use is essential. It reduces risks of pre-eclampsia, cutaneous neonatal lupus erythematosus, fetal growth restriction and prematurity. 11-13 In conclusion, HCQ is still in 2019, the cornerstone of the treatment of SLE.
- 1 June 2020
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 76, 104-106
Annual screening of comorbidities for people living with HIV in a single day hospitalization: A one-year experience
- 1 June 2020
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 76, 104-106
Annual screening of comorbidities for people living with HIV in a single day hospitalization: A one-year experience
- 1 April 2020
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 74, 115-116
Usefulness of serum amyloid a protein dosage for monitoring patients receiving tocilizumab
- 1 April 2020
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 74, 115-116
Usefulness of serum amyloid a protein dosage for monitoring patients receiving tocilizumab
- 1 March 2020
- Published by Elsevier in Joint Bone Spine
- Vol. 87 (2) , 179-180
Effectiveness and tolerance of off-label use of tocilizumab in autoimmune diseases: A Multicenter Study
- 1 March 2020
- Published by Elsevier in Joint Bone Spine
- Vol. 87 (2) , 179-180
Effectiveness and tolerance of off-label use of tocilizumab in autoimmune diseases: A Multicenter Study
- 1 February 2020
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 41 (2) , 98-105
Réglementation de la recherche médicale en France
- 1 February 2020
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 41 (2) , 98-105
Réglementation de la recherche médicale en France